Judd Midlam

Doctor of Pharmacy & Author of Syncope, publication: July 4, 2026. Advanced Reader's Copy (ARC) available now here:

[Judd Midlam @CJMidlam]

Fun interview publishing today on writing fiction, about technology, when science is moving too fast! https://t.co/u64ujC6b8N

[Judd Midlam @CJMidlam]

Pharma sector doubles down on AI amid hopes of slashing costs, timelines https://t.co/4ToruU2tfc

#AIpharma, #AIRandD

[Judd Midlam @CJMidlam]

What a fascinating agenda track - -

[Yasmin Hurd, PhD @neurovoice]

I’m looking forward to speaking at the @NIH WALS tomorrow ⚕️

I’ll be discussing our translational research to understand molecular mechanisms underlying addiction and related psychiatric risk relevant to potential treatment strategies.

💻 Tune in: https://t.co/ccynGfPrTN

[Yasmin Hurd, PhD @neurovoice]

I’m looking forward to speaking at the @NIH WALS tomorrow ⚕️

I’ll be discussing our translational research to understand molecular mechanisms underlying addiction and related psychiatric risk relevant to potential treatment strategies.

💻 Tune in: https://t.co/ccynGfPrTN

[Judd Midlam @CJMidlam]

@LxngevityLab Whatever it takes to cross the perpetually squiggly line into abstinence

[Judd Midlam @CJMidlam]

https://t.co/l1ir1CPKIe

[Judd Midlam @CJMidlam]

So good for Sunday vibes since ~2010. RMC BUDDHA-BAR Monte Carlo / Radio powered by Radio Monte Carlo https://t.co/Gvc2M0r8ke

[Judd Midlam @CJMidlam]

#neuroplastogens at scale is truly a fascinating idea

[Progress, Potential, And Possibilities @ProgressPotent1]

Psychedelic medicine has entered an entirely new era. 🧠🚀

What was once considered fringe science is now at the center of FDA discussions, White House policy initiatives, veteran mental health programs, and a rapidly growing biotech industry focused on neuroplasticity and precision psychiatry.

In this @ProgressPotent1 conversation, I sit down with
@EricSo168168, Co-Founder & Executive Chairman of
@Helus_Pharma, to explore:

• The rise of “next-generation” serotonergic agonists;
• Why psychedelic biotech is moving beyond psilocybin alone;
• The push for scalable neuroplasticity medicines;
• PTSD, depression, addiction & veteran mental health;
• FDA acceleration pathways and recent White House actions;
• Whether psychedelic therapies can realistically become standard of care;

We also discuss the broader evolution from counterculture psychedelics to mainstream pharmaceutical neuroscience - and the major scientific, regulatory, and commercial challenges still ahead.

#Psychedelics #MentalHealth #Neuroscience #Biotech #Psychiatry #PsychedelicMedicine #Neuroplasticity #HelusPharma #PrecisionPsychiatry #DepressionTreatment @rxMedyn @rxmedynamics

[Judd Midlam @CJMidlam]

@Josh__Hardman 😬😅

[JAMA Network Open @JAMANetworkOpen]

A single dose of #psilocybin was associated with rapid reduction in depressive symptoms in adults with major depressive disorder, with effects persisting beyond 3 months on secondary measures. https://t.co/5WISC7OOwi

[Orlando Economic Partnership @ORLPartnership]

Applications are now open for the Public Leadership Institute (PLI) Political Leadership Track—a nonpartisan program designed for professionals and business leaders looking to better understand public policy, governance, and public leadership

Apply today: https://t.co/rPBNstWMh4

[Judd Midlam @CJMidlam]

Check out an interview from this week on the science divide -- writing about fiction and contemporary science, business, technology. https://t.co/JVRVsQerWf

[Judd Midlam @CJMidlam]

@Rainmaker1973 In Syncope, AI-drug discovery goes awry when time slows. "The past and the future are clear but it’s the now that I cannot grasp. The concept of time is melting around me into a solicitude of moments punctuated by a realization that I still exist." https://t.co/defz5rqhpB

[Judd Midlam @CJMidlam]

@bryan_johnson The profundity of this idea is explored in my upcoming novel, Syncope, where an AI-drug development platform goes wrong. https://t.co/defz5rqhpB

[Judd Midlam @CJMidlam]

https://t.co/frHf1oPVvH

[Judd Midlam @CJMidlam]

The pharmaceutical industry is embracing AI, but finding new drugs this way remains elusive. Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development
https://t.co/kwdfnOxgdO via @WSJ

[Judd Midlam @CJMidlam]

FDA commissioner says decision on psychedelic treatments will be out 'quickly' https://t.co/4eb6S0ZvMH via @nbcnews

[Judd Midlam @CJMidlam]

Bookmark this one --> The Psychedelic Drug Development Tracker, for the latest on clinical trials and FDA registration. https://t.co/mkjxHvtaD0

[Judd Midlam @CJMidlam]

https://t.co/kWgHT9Dg2a 💡🧠
At least at the beginning of the period of abstention, addicts are encountering difficulties in following a strict therapeutic temporal regime, experiencing concomitantly a need to accelerate time as it passed.

[Judd Midlam @CJMidlam]

Un año con DuoLingo 🥳🥳 me encanta aprendido nuevas lenguas 🤗